Search results
Results from the Tech24 Deals Content Network
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The mean of analysts' price targets for NGM Biopharmaceuticals (NGM) points to a 461.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...
NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could ...
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
NASDAQ Biotechnology Index. The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ -listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. [1] A list of the 225 components of the index is published online .
In this article we will check out the progression of hedge fund sentiment towards NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) and determine whether it is a good investment right now. We at Insider ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify